Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses the storage and use of pyrilutamide for hair loss, where one user advises against keeping it in the freezer as it may crystallize the active compounds.

User asks if stacking Alfatradiol and Fluridil is effective for hair loss. Alfatradiol is a weaker, topical 5ar inhibitor, while Fluridil is an anti-androgen preventing DHT binding to hair follicles.

Topical diazoxide may be a promising hair regrowth treatment, especially for those who don't respond to minoxidil, as it activates potassium channels without needing sulfation. It appears safe for topical use, avoiding systemic effects seen in oral use.

The conversation discusses the best ethanol and propylene glycol ratio for homemade topical finasteride, with a focus on absorption and drying issues. The user shares their experience using a 50% propylene glycol, 30% ethanol, and 20% water solution, and considers adjusting the ethanol content for better results.

Dutasteride improved hair density and thickness in men who didn't respond to finasteride, with some experiencing transient sexual dysfunction. Users discussed switching from finasteride to dutasteride, noting initial shedding but eventual hair improvement.

The conversation discusses hair loss treatments, with the main focus on using Fluridil and considering switching to Pyrilutamide. Other treatments mentioned include minoxidil, topical finasteride, nizoral shampoo, and saw palmetto supplements, with advice to stick with Fluridil for at least six months before considering alternatives.

Taking potassium chloride and magnesium stopped minoxidil-induced palpitations. The user is considering continuing minoxidil with these supplements.

The user discusses using compounded oral minoxidil due to the ineffectiveness and inconvenience of topical minoxidil for diffuse thinning. They question the efficacy of compounded minoxidil compared to original tablet forms and express concerns about the importance of excipients and binders.

Finasteride is preferred over dutasteride due to its longer history, more research, and FDA approval, despite dutasteride being more potent. Users report varied side effects, influencing personal treatment choices.

Dutasteride may cause mental fog, vision blurriness, and sleep issues. Users suggest trying topical versions of the drug to mitigate side effects.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

The user has been using 1.25 mg of finasteride daily since June 2024 to promote hair regrowth and thickness, considering switching to dutasteride if results are unsatisfactory. They are hesitant to add minoxidil due to cost and potential side effects but have seen some progress with finasteride alone.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

Finasteride and dutasteride are discussed as preventative treatments for hair loss, with some advocating for early use and others concerned about side effects, especially before full maturity. Many regret not starting these treatments earlier due to their effectiveness in preventing or slowing hair loss.

The user switched from finasteride to dutasteride for hair loss treatment, but experienced increased libido, itchy scalp, and accelerated hair loss. Another user suggested that genetic variations might cause dutasteride to be less effective and recommended checking for specific genetic markers.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

The conversation is about the effectiveness of Fluridil (Eucapil) for hair loss compared to RU58841, with the original poster considering Fluridil a safer and potentially more effective alternative.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

A user experienced increased hair shedding and unchanged DHT levels after taking 0.25mg of finasteride for 47 days, leading them to increase the dose to 0.5mg. Others discussed varying experiences with finasteride, minoxidil, and the importance of measuring scalp DHT.

Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.

A user increased their finasteride dosage from 0.5 mg to 1 mg due to ongoing hair miniaturization, despite some improvement. They are considering dutasteride and have not used minoxidil, but are cautious about potential side effects.

The user experienced sexual side effects from finasteride and switched to using only topical minoxidil without side effects. They are seeking alternatives to finasteride, such as topical finasteride, to maintain hair without adverse effects.

The conversation discusses using RU58841 as a topical treatment for hair loss, with some users reporting no systemic issues. The original poster is considering RU58841 due to limited progress with dutasteride and oral minoxidil.

BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

A user is concerned about taking 1mg/day of finasteride due to potential gynecomastia, given their blood results. They seek advice on how their hormone levels might be affected by blocking DHT.